# Table of contents

* [ğŸ’Š The Decentralized FDA DAO](README.md)
* [â˜  Problems We Seek To Address](constitution/1-introduction-and-challenges.md)
  * [ğŸ¥« No Data on Unpatentable Molecules](1-introduction-and-challenges/no-data-on-unpatentable-molecules.md)
  * [ğŸ¤’ People With Rare Disease are Severely Punished](1-introduction-and-challenges/people-with-rare-disease-are-severely-punished.md)
  * [ğŸ”® Pre-Determining Clinical Endpoints Requires Psychic Powers](pre-determining-clinical-endpoints-requires-psychic-powers.md)
* [ğŸª™ Tokenomics](constitution/6-tokenomics.md)
* [ğŸ“ˆ Impact of Innovative Medicines on Life Expectancy](impact-of-innovative-medicines-on-life-expectancy.md)
* [ğŸ¯ Goals](constitution/2-solution.md)
  * [ğŸ­ More Cures and Less Lifelong Attempts at Masking Symptoms](more-cures-and-less-lifelong-attempts-at-masking-symptoms.md)
  * [ğŸ§ Greater Competitive Innovation and Fewer Monopolies](greater-competitive-innovation-and-fewer-monopolies.md)
  * [ğŸ‘€ Lower Costs of Validated Observational Research for Efficacy](lower-costs-of-validated-observational-research-for-efficacy.md)
  * [ğŸŒ Cost Savings from Decentralized Clinical Trials](cost-savings-from-decentralized-clinical-trials.md)
* [ğŸ“– References](constitution/12-references.md)
